Quotient Sciences Translational Pharmaceuticals Quotient Sciences Translational Pharmaceuticals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Flerie Invest","pharmaFlowCategory":"D","amount":"$23.6 million","upfrontCash":"Undisclosed","newsHeadline":"EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"ICELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"EpiEndo Pharmaceuticals"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Successful Completion of Phase I Study for Lead Asset EP395","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"ICELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"EpiEndo Pharmaceuticals"},{"orgOrder":0,"company":"EpiEndo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Commencement of LPS Challenge Trial for Lead Candidate EP395","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"ICELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"EpiEndo Pharmaceuticals"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              EpiEndo Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Iceland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Commencement of LPS Challenge Trial for Lead Candidate EP395

              Details:

              EP395 is an orally available macrolide or ‘Barriolide™‘ with reduced antimicrobial activity which aims to address the unmet medical need for a treatment for COPD (Chronic Obstructive Pulmonary Disease).

              Lead Product(s): EP395

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EpiEndo Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Iceland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Successful Completion of Phase I Study for Lead Asset EP395

              Details:

              EP395, is the first of EpiEndo’s orally available, non-antibiotic macrolides or ‘Barriolides™’, to enter clinical development and will be targeting chronic obstructive pulmonary disease (COPD).

              Lead Product(s): EP395

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              EpiEndo Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Iceland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EpiEndo Pharmaceuticals Secures EUR 20 Million Series A Funding to Advance Clinical Development of its Non-Antibiotic Macrolide for COPD

              Details:

              The financing secures funds to advance clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication.

              Lead Product(s): EP395

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: EP395

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Flerie Invest

              Deal Size: $23.6 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing August 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Douglas Pharma, a New Zealand success story, with CDMO capabilities for softgels, liquids, tablets, capsules & powders.
              Post Enquiry
              POST ENQUIRY